Literature DB >> 10709909

Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation.

M Z Wojtukiewicz1, M Rucinska, L Zimnoch, J Jaromin, Z Piotrowski, M Rózanska-Kudelska, W Kisiel, B J Kudryk.   

Abstract

Immunohistochemistry was applied to AMeX-fixed tissue sections of 12 adenocarcinomas of the stomach (seven intestinal adenocarcinomas and five diffuse carcinomas), 12 adenocarcinomas of the pancreas (nine ductal adenocarcinomas and three signet ring carcinomas), and 12 squamous cell carcinomas of the larynx obtained at surgical resection to examine the possibility of extravascular activation of blood coagulation in cancer tissues by exploring the in loco patterns of distribution of fibrinogen, a final product of blood coagulation, fibrin, and a by-product of coagulation reactions (prothrombin fragment 1+2). Gastric, pancreatic, and laryngeal cancers exhibited fibrinogen antigen in abundance throughout the tumor stroma. Fibrin was detected along the edges of nests of carcinoma cells and at the host-tumor interface. Prothrombin fragment 1+2 was present in the blood vessels in areas of neoangiogenesis at the host-tumor interface (gastric and pancreatic cancer tissues) and on the tumor cell bodies (pancreatic and laryngeal cancer tissues). The presence of prothrombin fragment 1+2 in cancer tissues appears to be a good indicator of coagulation activation and thrombin generation at the tumor burden.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709909     DOI: 10.1016/s0049-3848(99)00169-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

2.  Expression of functional protease-activated receptor 1 in human prostate cancer cell lines.

Authors:  Jian Liu; Manuela Bastian; Peter Kohlschein; Peter Schuff-Werner; Michael Steiner
Journal:  Urol Res       Date:  2003-03-25

3.  Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn
Journal:  Biomolecules       Date:  2021-04-29

4.  Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer.

Authors:  Hiroharu Yamashita; Joji Kitayama; Nobuko Kanno; Yutaka Yatomi; Hirokazu Nagawa
Journal:  BMC Cancer       Date:  2006-06-01       Impact factor: 4.430

5.  Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.

Authors:  Ewa Sierko; Marek Z Wojtukiewicz; Lech Zimnoch; Piotr Tokajuk; Krystyna Ostrowska-Cichocka; Walter Kisiel
Journal:  Ann Hematol       Date:  2013-10-26       Impact factor: 3.673

Review 6.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

7.  Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.

Authors:  John Castle; Emma Blower; Nigel J Bundred; James R Harvey; Jecko Thachil; Andrea Marshall; Karina Cox; Silvia Cicconi; Chris Holcombe; Carlos Palmieri; Cliona C Kirwan
Journal:  Trials       Date:  2020-08-27       Impact factor: 2.279

8.  Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.